Fibrations and Hasse diagrams for 6d SCFTs

We study the full moduli space of vacua of 6d worldvolume SCFTs on M5 branes probing an $A$-type singularity, focusing on the geometric incarnation of the discrete gauging mechanism which acts as a discrete quotient on the Higgs branch fibered over the tensor branch. We combine insights from brane constructions and magnetic quiver techniques, in which discrete gauging is implemented through the concept of decoration introduced in [arXiv:2202.01218]. We discover and characterize new transverse slices between phases of 6d SCFTs, identifying some of them with a family of isolated symplectic singularities recently discovered in [arXiv:2112.15494], and conjecturing the existence of two new isolated symplectic singularities

Magnetic quivers for rank 2 theories

In this note we construct magnetic quivers for the known rank-2 four dimensional $\mathcal{N}=2$ superconformal field theories. For every rank-1 theory one can find a unitary magnetic quiver; we observe that this is no longer possible at rank 2. Our list of magnetic quivers necessarily includes orthosymplectic quivers, in addition to unitary ones, of both the simply and non-simply laced variety. Using quiver subtraction, one can compute Higgs branch Hasse diagrams and compare with the results obtained via other methods finding nearly perfect agreement

S-fold magnetic quivers

Magnetic quivers and Hasse diagrams for Higgs branches of rank $r$ 4d $\mathcal{N}=2$ SCFTs arising from $\mathbb{Z}_{\ell}$ $\mathcal{S}$-fold constructions are discussed. The magnetic quivers are derived using three different methods: 1) Using clues like dimension, global symmetry, and the folding parameter $\ell$ to guess the magnetic quiver. 2) From 6d $\mathcal{N}=(1,0)$ SCFTs as UV completions of 5d marginal theories, and specific FI deformations on their magnetic quiver, which is further folded by $\mathbb{Z}_{\ell}$. 3) From T-duality of Type IIA brane systems of 6d $\mathcal{N}=(1,0)$ SCFTs and explicit mass deformation of the resulting brane web followed by $\mathbb{Z}_{\ell}$ folding. A choice of the ungauging scheme, either on a long node or on a short node, yields two different moduli spaces related by an orbifold action, thus suggesting a larger set of SCFTs in four dimensions than previously expected

Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.

BACKGROUND: Riociguat, a member of a new class of compounds (soluble guanylate cyclase stimulators), has been shown in previous clinical studies to be beneficial in the treatment of chronic thromboembolic pulmonary hypertension. METHODS: In this phase 3, multicenter, randomized, double-blind, placebo-controlled study, we randomly assigned 261 patients with inoperable chronic thromboembolic pulmonary hypertension or persistent or recurrent pulmonary hypertension after pulmonary endarterectomy to receive placebo or riociguat. The primary end point was the change from baseline to the end of week 16 in the distance walked in 6 minutes. Secondary end points included changes from baseline in pulmonary vascular resistance, N-terminal pro-brain natriuretic peptide (NT-proBNP) level, World Health Organization (WHO) functional class, time to clinical worsening, Borg dyspnea score, quality-of-life variables, and safety. RESULTS: By week 16, the 6-minute walk distance had increased by a mean of 39 m in the riociguat group, as compared with a mean decrease of 6 m in the placebo group (least-squares mean difference, 46 m; 95% confidence interval [CI], 25 to 67; P<0.001). Pulmonary vascular resistance decreased by 226 dyn · sec · cm-5in the riociguat group and increased by 23 dyn · sec · cm-5in the placebo group (least-squares mean difference, -246 dyn · sec · cm-5; 95% CI, -303 to -190; P<0.001). Riociguat was also associated with significant improvements in the NT-proBNP level (P<0.001) and WHO functional class (P = 0.003). The most common serious adverse events were right ventricular failure (in 3% of patients in each group) and syncope (in 2% of the riociguat group and in 3% of the placebo group). CONCLUSIONS: Riociguat significantly improved exercise capacity and pulmonary vascular resistance in patients with chronic thromboembolic pulmonary hypertension. (Funded by Bayer HealthCare; CHEST-1 and CHEST-2 ClinicalTrials.gov numbers, NCT00855465 and NCT00910429, respectively.) Copyright © 2013 Massachusetts Medical Society